Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S377100
Reexamination Certificate
active
07863313
ABSTRACT:
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.
REFERENCES:
patent: 2547493 (1951-04-01), Rowland
patent: 6831079 (2004-12-01), Yoon et al.
patent: WO03-013518 (2003-02-01), None
patent: WO 03013518 (2003-02-01), None
Wu and Farrelly, Toxicology 236:1-6, 2007.
Fukata et al., Yakugaku Zasshi (1974), 94(1), p. 36-43, in STN search report.
Bacher, M., et al., “An essential regulatory role for macrophage migration inhibitory factor in T-cell activation,”Proc. Natl. Acad. Sci. USA, 93(15):7849-7854 (Jul. 23, 1996).
Bozza, M., et al., “Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis,”J. Exp. Med., 189(2):341-346 (Jan. 18, 1999).
Bucala, R., “MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response,”FASEB J., 10(14):1607-1613 (Dec. 1996).
Calandra, T., et al., “MIF as a glucocorticoid-induced modulator of cytokine production,”Nature, 377(6544):68-71 (Sep. 7, 1995).
David, J.R., “Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction,”Proc. Natl. Acad. Sci. USA, 56(1):72-77 (Jul. 1966).
Donnelly, S.C., et al., “Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome,”Nat. Med., 3(3):320-323 (Mar. 1997).
Jüttner, S., et al., “Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha,”J. Immunol., 161(5):2383-2390 (Sep. 1, 1998).
Karimi, B., et al., “Efficient and chemoselective conversion of carbonyl compounds to 1,3-dioxanes catalyzed withN-bromosuccinimide under almost neutral reaction conditions,”Org. Lett., 1(11):1737-1739 (1999).
Lacey, D., et al., “Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor,”Arthritis Rheum., 48(1):103-109 (Jan. 2003).
Leech, M., et al., “Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of pro-inflammatory function and regulation by glucocorticoids,”Arthritis&Rheumatism, 42(8):1604-1608 (Aug. 1999).
Leech, M., et al., “Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant arthritis,”Arthritis&Rhermatism, 43(4):827-833 (Apr. 2000).
Leech, M., et al., “Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis,”Arthritis Rheum., 48(7):1881-1889 (Jul. 2003).
Liang, X., et al., “Solution-phase combinatorial synthesis using multicomponent Grignard reagents,”J. Chem. Soc., Perkin Trans. I, 2002:503-508 (2002).
Mimura, T., et al., “Platelet anti-aggregant activity of 2,2-dimethylthiazolidine hydrochloride and 2-(4-hydroxy-3-methoxyphenyl)thiazolidine,”Chem. Pharm. Bull., 36(3):1110-1116 (1988).
Mitchell, R.A., et al., “Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action,”J. Biol. Chem.,274(25):18100-18106 (Jun. 18, 1999).
Morand, E.F., et al., “Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis,”Arthritis&Rheumatism, 48(2):291-299 (Feb. 2003).
Perrin, C.L., et al., “Stereoelectronic control in addition of nucleophiles to an amidinium ion,”J. Am. Chem. Soc., 123:4451-4458 (2001).
Quallich, G.J., et al., “Synthesis of 1,2,3,4-tetrahydroisoquinolines containing electron-withdrawing groups,”J. Org. Chem., 63(12):4116-4119 (1998).
Robbe, Y., et al., “Radioprotection chimique comparée de diverses structures hétéro-cycliques pentagonales á deux hétéroatomes,”Eur. J. Med. Chem.—Chim. Ther., 17(3):235-243 (1982).
Sabroe, I., et al., “Asthma and MIF: innately Th1 and Th2,”Clin. Exp. Allergy, 30(9):1194-1196 (Sep. 2000).
Samajdar, S., et al., “A new molecular iodine-catalyzed thioketalization of carbonyl compounds: selectivity and scope,”Tetrahedron Lett., 42:4425-4427 (2001).
Sampey, A.V., et al., “Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes,”Mediators Inflamm., 9(3-4):125-132 (2000).
Sampey, A.V., et al., “Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor,”Arthritis Rheum, 44(6):1273-1280 (Jun. 2001).
Santos, L., et al., “Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids,”Clin. Exp. Immunol., 123(2):309-314 (Feb. 2001).
Santos, L.L., et al., “Suppression of adjuvant arthritis and synovial macrophage inducible nitric oxide by N-iminoethyl-L-ornithine, a nitric oxide synthase inhibitor,”Inflammation, 21(3):299-311 (Jun. 1997).
Spychala, J., “4-(Cyclic amidino)phenols- preparation and use in a diamidine synthesis,”Synthetic Communications, 30(6):1083-1094 (2000).
Srikrishna, A., et al., “A mild and simple procedure for the reductive cleavage of acetals and ketals,”Tetrahedron, 31(11):3339-3344 (1995).
Sumiya, F., et al., “Conjugated-triene intermediates in the Sommelet-Hauser rearrangement of cyclic 1-methyl-2-phenylammonium 1-methylides,”Chem. Pharm. Bull., 39(1):36-40 (Jan. 1991).
Weiser, W.Y., et al., “Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor,”Proc. Natl. Acad. Sci. USA, 86(19):7522-7526 (Oct. 1989).
Wenis, E., et al., “The synthesis of p-aminosalicyclic acid hydrochloride,”J. Am. Pharm. Assoc., 38:9-11 (1949) (Abstract only).
Wilk, I.J., et al., “The action of lithium aluminum hydride on 3-methyl-5-phenylhydantoin and 5-phenylhydantoin,”J. Org. Chem., 15:1020-1022 (1950).
Yus, M., et al., “A new and direct synthesis of 2-substituted pyrrolidines,”J. Org. Chem., 66(18):6207-6208 (2001).
Seeliger, STN File CA AN 64:36357 & DE 1206585 A, Dec. 9, 1965, CAS RN 10200-70-1.
Cashman et al., STN File CA AN 112:174715, “Oxygenation of dialkyl sulfides by modified sharpless reagent: a model system for the flavin-containing monooxygenase,” J. Am. Chem. Soc. 1990, 112(8), 3191-5, CAS RN 127732-82-5.
Langer et al., STN File CA AN 85:5050, “Attempted conformational alterations on cyclic systems, part 4. Ring distortations and rotameric behaviour of the phenyl group in 2,2-disubstituted-1,3-dioxantes,” Monatsh. Chem., 1976, 107(1), 1-17, CAS RN 59356-52-4.
Kalff et al., STN File CA AN 65:29021, “Conformation of non-aromatic ring compounds. XX. Dipole moments and N.M.R. spectra of some 2-substituted 1,3-dithianes,” Rec. Trav. Chim. Pays-Bas, 1966, 85(5), 467-84, CAS RN 10359-12-3.
Alderweireldt et al., STN File CA AN 64:51391, “Nuclear magnetic resonance experiments on ketals. V. Conformation of 2-substituted 1,3-dioxolanes,” Bull. Soc. Chim. Belges, 1965, 74(11-12), 488-505, CAS RN 6135-56-4.
Das et al., STN File CA AN 77:87199, “Substitute effects on molecular ion abundance,” Ind. J. Chem., 1972, 10(3), 277-278, CAS RN 36881-02-4.
Suzuki et al., STN File CA AN 101:22812, “Photochemical reactions of 2-(4-substituted pheny1)-2-thiazolines: cycloelimination of benzonitriles and ethylene sulfide and dehydrogenation to thiazoles,” Research Reports of th
Iskander Magdy Naguib
Morand Eric Francis
Skene Colin Edward
Chu Yong
Cortical PTY LTD
King & Spalding LLP
LandOfFree
Methods for the treatment of inflammatory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of inflammatory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of inflammatory diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2736759